Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Results of a study showed Ibrutinib was superior to chlorambucil in previously untreated patients with CLL based on progression-free survival, overall survival, response rate, and improvement in hematologic variables.